Sunshine Biopharma, Inc. (SBFM)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Steve N. Slilaty Ph.D. | CEO, President & Chairman | 640k | -- | 1952 |
Mr. Camille Sebaaly | CFO & Secretary | 695k | -- | 1959 |
Dr. Abderrazzak Merzouki | Chief Science Officer & Director | 340k | -- | 1964 |
Mr. Marc Beaudoin | Chief Operating Officer | -- | -- | 1967 |
Mr. Malek Chamoun | Chief Development Officer | -- | -- | 1985 |
Mr. Robert G. Ferreira | President of Sunshine Bio Investments Inc | -- | -- | 1962 |
Sunshine Biopharma, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 44
Description
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
Corporate Governance
Upcoming Events
August 9, 2024 at 12:30 PM UTC - August 13, 2024 at 12:30 PM UTC
Sunshine Biopharma, Inc. Earnings Date